We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blocking MicroRNA Synthesis Reverses Behavior of Tumor-Associated Macrophages

By LabMedica International staff writers
Posted on 22 Jun 2016
Preventing synthesis of microRNAs in compromised tumor associated macrophages (TAMs) reprograms these cells from being tumor supporting to being tumor suppressing.

TAMs largely express an alternatively activated (or M2) phenotype, which entails immunosuppressive and tumor-promoting capabilities. More...
Reprogramming TAMs towards a classically activated (M1) phenotype might reverse tumor-associated immunosuppression and activate anti-tumor immunity.

To test this possibility, investigators at Ecole Polytechnique Fédérale de Lausanne (Switzerland) used genetic engineering techniques to conditionally delete the microRNA (miRNA)-processing enzyme DICER1 in macrophages. The enzyme Dicer, which is encoded by the DICER1 gene, trims double stranded RNA, to form small interfering RNA (siRNA) or microRNA (miRNA). These processed RNAs are incorporated into the RNA-induced silencing complex (RISC), which targets messenger RNA to prevent translation.

The investigators reported in the June 13, 2016, online edition of the journal Nature Cell Biology that deletion of DICER1 prompted M1-like TAM programming, characterized by hyperactive IFN (interferon)-gamma/STAT1 (signal transducer and activator of transcription 1) signaling. This behavior modification eliminated the immunosuppressive capacity of TAMs and fostered the recruitment of activated cytotoxic T lymphocytes (CTLs) to the tumors. CTL-derived IFN-gamma increased the M1 polarization of DICER1-deficient TAMs and inhibited tumor growth.

Genetic rescue of Let-7 miRNA activity in DICER1-deficient TAMs partly restored their M2-like phenotype and decreased tumor-infiltrating CTLs. These findings suggested that DICER1/Let-7 microRNA activity opposed IFN-gamma-induced, immunostimulatory M1-like TAM activation.

"The most exciting finding was that TAM reprogramming greatly improved the efficacy of immunotherapy," said senior author Dr. Michele De Palma, a tenure track assistant professor at the Ecole Polytechnique Fédérale de Lausanne. "Our results in experimental models of cancer suggest a new therapeutic strategy based on inhibiting the microRNA machinery - or the Let-7 microRNAs - specifically in the TAMs, which may unleash the power of mainstream immunotherapies, such as immune checkpoint inhibitors."

Related Links:
Ecole Polytechnique Fédérale de Lausanne


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.